The Most Advanced Drug Discovery Robot in the World
The world’s most advanced drug discovery robot is working alongside our scientists to help make drug discovery smarter, faster and cheaper. Designed to work three times more quickly than previous drug discovery robots, NiCoLA-B is also more scientist-friendly, flexible and responsive.
"We can configure NiCoLA-B to do our experiments in whatever way we want and we can interact with it while it’s working. It can sense our presence in a way that previous robots couldn’t, so it can share our workspace instead of being encased behind safety guarding." Paul Harper, Associate Principal Scientist – Screening Sciences at the Innovative Medicines and Early Development Biotech Unit.
A friendlier robot
Harper and his colleagues drew on decades of experience working with first generation robots to draw up their blueprint for NiCoLA-B. They wanted to swap the so-called ‘dumb robots’ originally designed for heavy lifting on production lines for a bespoke robotic system suited to the delicate manoeuvres and human interactions needed in drug discovery.
“We used to have to adjust our experiments to the way the robots worked, but NiCoLA-B has been designed to adapt to our way of working and collaborate with us. At any time, we can quickly inspect, interact and easily reconfigure it to our changing needs, so we’re in charge now!” Harper explains.
Through a mobile app, the team is able to ‘talk’ to NiCoLA-B and guide its decision-making – day or night, from their offices, homes, or even from the other side of the world.
NiCoLA-B – on duty 24/7
NiCoLA-B uses sound waves to move tiny droplets of potential drugs from storage tubes into miniature ‘wells’ on assay plates – billionths of a litre at a time. Next, droplets of cells or biochemical solutions are added to the wells. NiCoLA-B then oversees the interactions between the contents of the wells, checking for potential activity that could indicate a promising new drug.
Sharing NiCoLA-B with research partners
We are making NiCoLA-B available to our research partners through Open Innovation – our pioneering initiative for sharing our compounds, technology and expertise with academic and industry collaborators. The first research partners to work with NiCoLA-B are Cancer Research UK and the Medical Research Council. By combining our expertise, we are accelerating medicines research for the treatment of a range of diseases where there is a substantial unmet need.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Allergy Amplifier Implicated in Asthma Also Intensifies Food AllergyNews
Scientist who previously reported that a small protein, aptly named histamine-releasing factor, played a pro-inflammatory role in asthma have now shown that it also serves as a “food allergy amplifier”. This work paves the way for blood tests to predict which patients will respond to allergy therapy, and strongly supports the idea that drugs designed to block HRF could prevent food allergy attacks.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE